PND7 COST-EFFECTIVENESS OF CLADRIBINE COMPARED TO NATALIZUMAB, OCRELIZUMAB AND ALEMTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS IN CHILE
Abstract
Authors
M.A. Espinoza C. Balmaceda R. Rojas